Description: Valeo Pharma Inc. acquires and markets specialty products in the United States and Canada. Its product portfolio includes Synacthen, a neurology therapeutic for the treatment of severe multiple sclerosis and gout; and M-Eslon, an extended release morphine sulphate used for pain management. The company also offers Ondansetron ODT for prevention of nausea and vomiting caused by cancer chemotherapy; Benztropine, an anticholinergic agent used for the treatment of Parkinson's disease; and Onstryv, a safinamide tablet used to treat idiopathic Parkinson's disease. In addition, it develops Ethacrynate Sodium, a loop diuretic used to treat high blood pressure, as well as the swelling caused by diseases, such as congestive heart failure, liver failure, and kidney failure. The company was founded in 2003 and is headquartered in Kirkland, Canada.
Home Page: www.valeopharma.com
16667 Hymus Boulevard
Kirkland,
QC
H9H 4R9
Canada
Phone:
514 694 0150
Officers
| Name | Title |
|---|---|
| Mr. Kyle Steiger | Senior VP & Chief Commercial Officer |
| Mr. Al Moghaddam B. Com. Cma | Chief Executive Officer |
| Mr. Pascal Tougas | Chief Financial Officer |
| Mr. Frédéric Dumais | Director of Communications & Investor Relations |
| Mr. Guy-Paul Allard | VP of Legal Affairs & Corporate Secretary |
| Mr. Jean Francois Fournier | Head of Ophthalmology Business Unit |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 21.2314 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 66.7468 |
| Price-to-Sales TTM: | 0.0867 |
| IPO Date: | |
| Fiscal Year End: | October |
| Full Time Employees: | 70 |